INOVIO PHARMACEUTICALS, INC. | Business Contracts

Separation Agreement, dated as of May 10, 2022, by and between the registrant and J. Joseph Kim (Filed With SEC on August 9, 2022)

ATM Equity OfferingSM Sales Agreement dated November 9, 2021 by and among Inovio Pharmaceuticals, Inc., BofA Securities, Inc., RBC Capital Markets, LLC and Oppenheimer & Co. Inc (Filed With SEC on November 9, 2021)

Underwriting Agreement, dated January 20, 2021, by and among the Company and the Representatives of the several Underwriters named therein (Filed With SEC on January 22, 2021)

Other Transaction Authority For Prototype Agreement dated June 22, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (Filed With SEC on August 10, 2020)

Amended and Restated Collaboration and License Agreement dated June 7, 2021, by and between Inovio Pharmaceuticals, Inc. and Advaccine Biopharmaceuticals Suzhou Co., Ltd (Filed With SEC on August 9, 2021)

Collaboration and License Agreement dated December 31, 2020 between Inovio Pharmaceuticals, Inc. and Advaccine Biopharmaceuticals Suzhou Co., Ltd (Filed With SEC on March 1, 2021)

Award Agreement dated June 18, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (Filed With SEC on August 10, 2020)

At-The-Market Equity Offering Sales Agreement dated April 3, 2020 between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on April 3, 2020)

Employment Agreement dated March 8, 2019 between Inovio Pharmaceuticals, Inc. and Jacqueline E. Shea (Filed With SEC on March 12, 2020)

Employment Agreement dated as of March 4, 2019 between Inovio Pharmaceuticals, Inc. and Laurent M. Humeau (Filed With SEC on March 12, 2020)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 12, 2020)

Amendment No. 2 to the At-The-Market Equity Offering Sales Agreement dated March 9, 2020 between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on March 9, 2020)

Amendment No. 1 to the At-The-Market Equity Offering Sales Agreement dated February 7, 2020 between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on February 7, 2020)

Registration Rights Agreement, dated December 26, 2019, by and between the Company and the Purchaser (Filed With SEC on January 2, 2020)

Convertible Bonds Subscription Agreement, dated December 26, 2019, by and between the Company and the Purchaser (Filed With SEC on January 2, 2020)

Convertible Bonds Subscription Agreement, dated July 31, 2019, by and among the Company and the Purchasers (Filed With SEC on August 6, 2019)

Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan, as amended (Filed With SEC on May 10, 2019)

Separation Agreement dated March 26, 2019 by and between Inovio Pharmaceuticals, Inc. and Dr. Mark Bagarazzi (Filed With SEC on May 9, 2019)

Consulting Agreement dated February 21, 2019 by and between Inovio Pharmaceuticals, Inc. and Dr. Niranjan Sardesai (Filed With SEC on March 12, 2019)

Indenture, dated as of February 19, 2019, by and between the Company and U.S. Bank National Association, as trustee (Filed With SEC on February 20, 2019)

INOVIO PHARMACEUTICALS, INC. (20)